Crescent Biopharma (CBIO) Stock Overview
A biotechnology company, researches and develops cancer therapy candidates in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CBIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Crescent Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.89 |
| 52 Week High | US$27.41 |
| 52 Week Low | US$8.72 |
| Beta | 0 |
| 1 Month Change | -1.52% |
| 3 Month Change | -3.87% |
| 1 Year Change | 30.73% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.93% |
Recent News & Updates
Crescent Biopharma: Intriguing Developer Of ADC/PD1-VEGF Assets May Not Be Sufficiently Derisked
Summary Crescent Biopharma is developing CR-001, a PD-1 x VEGF bispecific antibody, aiming to rival Keytruda as an immuno-oncology backbone. I see Crescent's dual strategy—advancing CR-001 and building a best-in-class ADC portfolio—as a bold but high-risk approach in a competitive landscape. Despite promising mechanisms, near-term catalysts are limited, and clinical proof for CR-001, CR-002, and CR-003 remains lacking. I rate CBIO a Hold, preferring to wait for derisking clinical data before considering a more aggressive position. Read the full article on Seeking AlphaRainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic
Shareholders in Crescent Biopharma, Inc. ( NASDAQ:CBIO ) may be thrilled to learn that the analysts have just delivered...Recent updates
Shareholder Returns
| CBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.0% | 0.6% | -0.2% |
| 1Y | 30.7% | 36.5% | 12.1% |
Return vs Industry: CBIO underperformed the US Biotechs industry which returned 36.5% over the past year.
Return vs Market: CBIO exceeded the US Market which returned 12.1% over the past year.
Price Volatility
| CBIO volatility | |
|---|---|
| CBIO Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CBIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CBIO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2024 | 69 | Josh Brumm | crescentbiopharma.com |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Crescent Biopharma, Inc. Fundamentals Summary
| CBIO fundamental statistics | |
|---|---|
| Market cap | US$722.91m |
| Earnings (TTM) | -US$165.12m |
| Revenue (TTM) | US$11.88m |
Is CBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBIO income statement (TTM) | |
|---|---|
| Revenue | US$11.88m |
| Cost of Revenue | US$0 |
| Gross Profit | US$11.88m |
| Other Expenses | US$177.01m |
| Earnings | -US$165.12m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.86 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,389.58% |
| Debt/Equity Ratio | 0% |
How did CBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 06:14 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Crescent Biopharma, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Bradley Canino | Guggenheim Securities, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |